SPMC
FAMOTIDINE TABLETS USP 20 mg

PRESENTATION:

Famotidine tablets USP 20 mg packs of 1000 tablets and Blister 200's (20x10). Each light blue color, circular bi convex coated tablets contain Famotidine USP 20 mg.

INDICATIONS DOSAGE:

Treatment of benign gastric and duodenal ulceration

Adult: 40 mg once daily for 4–8 weeks, dose to be taken at night

Maintenance treatment of duodenal ulceration

Adult: 20 mg once daily, dose to be taken at night

Reflux oesophagitis

Adult: 20–40 mg twice daily for 6–12 weeks; maintenance 20 mg twice daily

SIDE EFFECTS:

Uncommon Appetite decreased. dry mouth. taste altered. Vomiting

Rare or very rare Anxiety. chest tightness. drowsiness. insomnia. interstitial pneumonia. libido decreased. muscle cramps. neutropenia. paraesthesia. Psychiatric disorder. seizures. severe cutaneous adverse reactions (SCARs

ADMINISTRATION:

May be taken with or without food.

CAUTIONS:

This drug may cause dizziness, headache or confusion, if affected, do not drive or operate machinery.

PREGNANCY:

advise avoid unless potential benefit outweighs risk.

Pregnancy Category (US FDA)

IV/Parenteral/PO: B

BREAST FEEDING:

Present in milk—not known to be harmful but advises avoid.

RENAL IMPAIRMENT:

Seizures reported very rarely. Dose adjustments Use normal dose every 36–48 hours or use half normal dose if eGFR less than 50 mL/minute/1.73 m2.

CrCl (mL/min)	Dosage
<50 to <10	Reduce dose to half or prolong dosing interval to 36-48 hours based on clinical response.

MONITORING PARAMETERS:

Monitor CBC, gastric pH, liver function (prolonged use), and occult blood with gastrointestinal bleeding.

SPECIAL PRECAUTION:

Patient with chronic lung disease and diabetes. Immunocompromised or intubated (in ICU setting) patient. Rule out gastric malignancy or possibility of malignancy prior to therapy. Renal impairment. Children. Pregnancy and lactation.

CONTRAINDICATION:

Famotidine should not be administered to patients with a history of hypersensitivity to other H_2-receptor antagonists.

PATIENT COUNSELING INFORMATION:

This drug may cause dizziness, headache or confusion, if affected, do not drive or operate machinery.

INTERACTIONS:

May decrease serum concentrations of atazanavir, cefditoren, delavirdine, ketoconazole, and fosamprenavir. May decrease the absorption of dasatinib. Probenecid inhibits the renal tubular secretion of famotidine. Antacids may reduce the absorption of famotidine.

STORAGE:

Keep tightly closed in cool and dry place. Protect from light. Store below 30^0C. do not crush or chew tablets. Keep away from children.

Manufactured by:
State Pharmaceutical Manufacturing Corporation
No.11, Sir John Kotalawala Mawatha,
Kandawala Estate, Ratmalana, Sri Lanka.